Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 9/20 | 0.40 |
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA9 | Q16790 | 9/20 | 0.40 |
| ▸ | RXRA | P19793 | 7/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718371 | 0.91 | GPR119 (0.42) | LOXL2CA12CA1CA2CA9 | |
| SCHEMBL720485 | 0.90 | LOXL2 (0.43) | LOXL2CA12CA1CA2CA9 | |
| Tert-Butyl Formate SCHEMBL28786710 | 0.74 | LOXL2 (0.44) | LOXL2CA12CA1CA2CA9 | |
| SCHEMBL4289925 | 0.73 | GPR119 (0.61) | GPR119 | |
| SCHEMBL16242409 | 0.72 | GPR119 (0.46) | LOXL2GPR119 | |
| SCHEMBL722541 | 0.67 | GPR119 (0.48) | CA12CA1CA2CA9CA7 | |
| SCHEMBL720852 | 0.67 | GPR119 (0.51) | PTGS2GPR119 | |
| SCHEMBL22663349 | 0.64 | CYP11B1 (0.36) | RXRAGRIN1GRIN2B | |
| SCHEMBL2552046 | 0.64 | GPR119 (0.61) | GPR119 | |
| SCHEMBL12283329 | 0.64 | GPR119 (0.61) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | LOXL2 3276/4885CA12 2010/4885CA1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.